NaDeNo’s lead candidate PACAB-002 is granted Orphan Drug Designation

The European Medicines Agency (EMA) has granted orphan drug designation to PACAB-002, NaDeNo’s investigational treatment for patients with ovarian cancer.

PACAB-002 is designed to target peritoneal micrometastases that are difficult to eradicate with current standard-of-care treatment. This is an important challenge in ovarian cancer as intraperitoneal recurrence is a key driver of poor survival.

In granting the designation, the EMA recognises the strong preclinical efficacy data of PACAB-002 and its potential to provide a clinically relevant benefit over existing treatment options in ovarian cancer.